Detection of glioblastoma response to temozolomide combined with bevacizumab based on µMRI and µPET imaging reveals [18F]-fluoro-l-thymidine as an early and robust predictive marker for treatment efficacy

摘要: The individualized care of glioma patients ought to benefit from imaging biomarkers as precocious predictors therapeutic efficacy. Contrast enhanced MRI and [18F]-fluorodeoxyglucose (FDG)–PET are routinely used in clinical settings; their ability forecast the response is controversial. objectives our preclinical study were analyze sensitive µMRI and/or µPET predict efficacy anti-angiogenic chemotherapeutic regimens. Human U87 U251 orthotopic models implanted nude rats. Temozolomide bevacizumab administered. (anatomical, diffusion, microrheological parameters) ([18F]-FDG [18F]-fluoro-l-thymidine [FLT]–PET) studies undertaken soon (t1) after treatment initiation compared with late anatomical evaluation tumor volume (t2) overall survival. In both models, FDG FLT uptakes attenuated at t1 temozolomide alone or bevacizumab. distribution FLT, reflecting intratumoral heterogeneity, was also modified. less predictive for than (also highly correlated outcome, P < .001 models). Cerebral blood significantly decreased by + survival rats implants. While efficacy, a combination superior any one (P .0001 tumors outcome). Our results indicate that predictor predictability biomarkers. These findings may translate clinically treatments could be decided given PET/MRI examinations.